Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable ...
PTC (NASDAQ:PTC) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, ...
Nearly six months ago, PTC Therapeutics reported positive interim data for a drug in mid-stage development for Huntington’s disease, an inherited neurological disorder with limited treatment options ...
In the latest quarter, 11 analysts provided ratings for PTC (NASDAQ:PTC), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results